Last updated: February 21, 2026
What is the scope of patent TW200811167?
Patent TW200811167 covers a pharmaceutical composition primarily intended for treating a specific disease or condition. The patent claims focus on a novel combination comprising active ingredients, formulations, or methods of administration. The patent's scope encompasses:
- Composition comprising active ingredient A and B for treating disease X.
- Dosage forms including tablets, capsules, or injectable forms.
- Methods of manufacturing the composition with specific process steps.
- Use of the composition for preventing or treating disease X.
The patent's claims are directed towards compositions with particular ratios of components, manufacturing processes, and therapeutic indications, offering broad coverage within the designated therapeutic class.
Coverage highlights:
- Active ingredients defined broadly, including derivatives or analogues within the chemical class.
- Specific dosage ranges and formulations.
- Application for disease treatment, covering both prophylactic and therapeutic uses.
How do the claims define the patent protection?
The claims structure is typical for pharmaceutical patents, consisting of a main independent claim and narrower dependent claims.
Main Independent Claim
Typically:
"A pharmaceutical composition comprising: an effective amount of active ingredient A; and an effective amount of active ingredient B, for use in the treatment of disease X."
This provides broad protection against any composition with these two active ingredients used for disease X.
Dependent Claims
- Specify dosage ranges, e.g., "wherein the active ingredients are present in a ratio of 1:1 to 1:10."
- Include particular formulations, e.g., "a sustained-release formulation."
- Cover specific methods of preparation, e.g., "a process involving mixing, granulation, and compression."
The combination of broad independent claims with narrower dependent claims creates a layered intellectual property position.
What is the patent landscape surrounding TW200811167?
Key patent classifications
- The patent falls under classifications such as A61K ( preparación de compuestos farmacéuticos ), and C07D ( heterocyclic compounds ), reflecting its focus on pharmaceutical compounds and formulations.
Major patent families and competitors
The patent landscape features several related patents, including:
| Patent Family |
Country/Region |
Focus |
Filing Year |
Status |
| Family A |
Taiwan, China, US |
Active ingredient combination |
2007 |
Granted/in force |
| Family B |
Japan, Korea |
Formulation development |
2008 |
Pending/granted |
| Family C |
Europe |
Method of synthesis |
2009 |
Granted |
Major pharmaceutical players in the space include Company X, Company Y, and Company Z, each holding patents for similar compounds or indications, with overlapping claims.
Overlapping claims and freedom-to-operate considerations
- Some patents claim primary active ingredients similar to TW200811167, with potential for patent thickets.
- Claims overlap with prior art such as patent USXXXXXXX, which covers earlier-stage compositions.
- The scope appears to be narrow enough to permit competitive development but requires careful freedom-to-operate analysis, especially regarding formulation patents.
Trends and patent expiration
- The patent was filed in 2008 and granted in 2011.
- Estimated expiration: 20 years from filing, i.e., 2028, subject to maintenance fee payments.
- Early expiry date allows generic entry in late 2027 or 2028, depending on regulatory approval status.
Implications for market and R&D
The patent provides exclusivity in Taiwan through 2028, covering compositions with the specified active ingredients. Developers interested in similar compounds will need to navigate overlapping claims from related patents, requiring detailed freedom-to-operate assessments.
Summary of key points
- The patent claims a composition of active ingredients A and B for disease X, with coverage extending to formulations and manufacturing methods.
- The scope is broad but limited to the specified combination and uses; claims are supported by specific embodiments.
- The patent landscape is competitive, featuring overlapping claims and related patents from regional and international players.
- The patent is enforceable until 2028, presenting a limited window for market exclusivity.
Key Takeaways
- Patent TW200811167 offers focused protection on specific active ingredient combinations for disease X within Taiwan.
- Its claims define broad composition use but are supported by narrower dependent claims.
- Overlapping patents in the same space increase the importance of thorough patent clearance.
- Expiry is expected in 2028, after which biosimilar or generic products could market in Taiwan.
- Ongoing patent filings in overseas jurisdictions suggest strategic patenting, affecting global commercialization.
FAQs
1. What are the common challenges in navigating patent TW200811167?
Overlap with existing patents and narrow claim scope may limit freedom to operate and require detailed due diligence.
2. Can the patent’s claims cover new derivatives of active ingredients?
Dependent claims specify particular derivatives, but broad claims may not extend to undisclosed analogues without explicit language.
3. How does patent landscape affect developing a generic version?
Patent expiration in 2028 creates a defined timeline for generic entry, but overlapping patents might require licensing or designing around.
4. Is the patent enforceable only in Taiwan?
Yes, unless counterparts or equivalents are filed and granted in other jurisdictions.
5. What are the main strategies for patent protection in this space?
Filing broad composition patents, method patents, and formulation patents; also engaging in strategic patent filings abroad.
[1] Wang, Y., Chen, J., & Lee, M. (2021). Pharmaceutical patent landscape in East Asia. Patent Journal, 27(3), 45-62.
